150 related articles for article (PubMed ID: 10887633)
1. Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
Oncology (Williston Park); 2000 Jun; 14(6):828, 830. PubMed ID: 10887633
[No Abstract] [Full Text] [Related]
2. Managing advanced prostate cancer with Viadur (leuprolide acetate implant).
Moul JW; Civitelli K
Urol Nurs; 2001 Dec; 21(6):385-8, 393-4; quiz 395-6. PubMed ID: 11998504
[TBL] [Abstract][Full Text] [Related]
3. What should I know about Lupron Depot for treating prostate cancer?
Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):7. PubMed ID: 22396997
[No Abstract] [Full Text] [Related]
4. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
5. Implantable LHRH agonist for treatment of prostate cancer.
Lajiness MJ
Urol Nurs; 2006 Oct; 26(5):408, 414. PubMed ID: 17078331
[No Abstract] [Full Text] [Related]
6. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.
Fowler JE; Flanagan M; Gleason DM; Klimberg IW; Gottesman JE; Sharifi R
Urology; 2000 May; 55(5):639-42. PubMed ID: 10792069
[TBL] [Abstract][Full Text] [Related]
7. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
Boccon-Gibod L; Iversen P; Persson BE
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
[TBL] [Abstract][Full Text] [Related]
8. Anaphylaxis to leuprolide acetate depot injection during treatment for prostate cancer.
Grant JP; Levinson AW
Clin Genitourin Cancer; 2007 Mar; 5(4):284-6. PubMed ID: 17553209
[TBL] [Abstract][Full Text] [Related]
9. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
Crawford ED; Moul JW; Sartor O; Shore ND
Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
[TBL] [Abstract][Full Text] [Related]
10. Leuprolide acetate-induced generalized papular eruption.
Burris K; Ding CY; Lim GF
J Drugs Dermatol; 2014 Jun; 13(6):755-7. PubMed ID: 24918569
[TBL] [Abstract][Full Text] [Related]
11. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
Pollack A; Horwitz EM
Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
[No Abstract] [Full Text] [Related]
12. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
[No Abstract] [Full Text] [Related]
13. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
14. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry EA; Sweeney CJ
J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
[No Abstract] [Full Text] [Related]
15. Hypersensitivity vasculitis associated with leuprolide (Lupron).
Gnanaraj J; Saif MW
Cutan Ocul Toxicol; 2010 Sep; 29(3):224-7. PubMed ID: 20470239
[TBL] [Abstract][Full Text] [Related]
16. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
Kaku H; Tsushima T; Nasu Y; Kumon H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
[No Abstract] [Full Text] [Related]
17. Leuprolide acetate-induced dermatitis herpetiformis.
Grimwood RE; Guevara A
Cutis; 2005 Jan; 75(1):49-52. PubMed ID: 15732435
[TBL] [Abstract][Full Text] [Related]
18. Depression during hormonal treatment of prostate cancer.
Rosenblatt DE; Mellow A
J Am Board Fam Pract; 1995; 8(4):317-20. PubMed ID: 7572297
[No Abstract] [Full Text] [Related]
19. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
Montgomery BS; Borwell JP; Higgins DM
Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
Shore ND; Sieber P; Schimke L; Perzin A; Olsen S
Urol Nurs; 2013; 33(5):236-44, 248. PubMed ID: 24354113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
